Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kimberley K. Fox is active.

Publication


Featured researches published by Kimberley K. Fox.


BMC Public Health | 2004

Barriers to asymptomatic screening and other STD services for adolescents and young adults: focus group discussions

Elizabeth C. Tilson; Victoria Sanchez; Chandra L. Ford; Marlene Smurzynski; Peter A. Leone; Kimberley K. Fox; Kathleen Irwin; William C. Miller

BackgroundSexually transmitted diseases (STDs) are a major public health problem among young people and can lead to the spread of HIV. Previous studies have primarily addressed barriers to STD care for symptomatic patients. The purpose of our study was to identify perceptions about existing barriers to and ideal services for STDs, especially asymptomatic screening, among young people in a southeastern community.MethodsEight focus group discussions including 53 White, African American, and Latino youth (age 14–24) were conducted.ResultsPerceived barriers to care included lack of knowledge of STDs and available services, cost, shame associated with seeking services, long clinic waiting times, discrimination, and urethral specimen collection methods. Perceived features of ideal STD services included locations close to familiar places, extended hours, and urine-based screening. Television was perceived as the most effective route of disseminating STD information.ConclusionsFurther research is warranted to evaluate improving convenience, efficiency, and privacy of existing services; adding urine-based screening and new services closer to neighborhoods; and using mass media to disseminate STD information as strategies to increase STD screening.


The Journal of Infectious Diseases | 1997

Antimicrobial Resistance in Neisseria gonorrhoeae in the United States, 1988–1994: The Emergence of Decreased Susceptibility to the Fluoroquinolones

Kimberley K. Fox; Joan S. Knapp; King K. Holmes; Edward W. Hook; Franklyn N. Judson; Sumner E. Thompson; John A. Washington; William L. H. Whittington

Antimicrobial susceptibilities of Neisseria gonorrhoeae have been prospectively determined in the Gonococcal Isolate Surveillance Project of the Centers for Disease Control and Prevention. From 1988 through 1994, susceptibilities were determined for 35,263 isolates from 27 clinics. Patients were demographically similar to those in nationally reported gonorrhea cases. In 1994, 30.5% of isolates had chromosomally or plasmid-mediated resistance to penicillin or tetracycline. Penicillin resistance increased from 1988 (8.4%) to 1991 (19.5%) and then decreased in 1994 (15.6%). Tetracycline resistance decreased from 1988 (23.4%) to 1989 (17.3%) and then increased in 1994 (21.7%). Most isolates (99.9%) were highly susceptible to broad-spectrum cephalosporins. Isolates with decreased susceptibility to ciprofloxacin increased from 1991 (0.4%) to 1994 (1.3%); 4 isolates were ciprofloxacin-resistant. Ciprofloxacin-resistant strains may not respond to therapy with recommended doses of fluoroquinolones, and the clinical importance of strains with decreased susceptibility is unknown. The emergence of fluoroquinolone resistance in N. gonorrhoeae in the United States threatens the future utility of this class of antimicrobials for gonorrhea therapy.


Sexually Transmitted Diseases | 1998

Gonorrhea in the United States, 1981-1996. Demographic and geographic trends.

Kimberley K. Fox; William L. H. Whittington; William C. Levine; John S. Moran; Akbar A. Zaidi; Allyn K. Nakashima

Objective: To describe demographic and geographic trends in gonorrhea incidence in the United States from 1981 through 1996. Study Design: We analyzed aggregate gonorrhea cases reported to the Centers for Disease Control and Prevention by the 50 states, District of Columbia, and 63 large cities. Annual incidence rates (cases/100,000 persons) were calculated. Results: Between 1981 and 1996, the incidence of reported gonorrhea decreased 71.3%, from 431.5 to 124.0 cases/100,000. However, rates among blacks were 35 times higher than rates among whites in 1996 (684.6 versus 19.4) compared with 11 times higher in 1981 (1,894.3 versus 164.3). Among women of all races, 15 to 19 year olds had the highest rates (716.6 in 1996), whereas among men, 20 to 24 year olds had the highest rates (512.9 in 1996). Southern states had higher rates than other regions. Conclusions: Large segments of the population, including adolescents, young adults, and blacks, continue to have high rates of gonococcal infection; prevention programs and health care providers should address the needs of these groups.


Journal of Acquired Immune Deficiency Syndromes | 2009

National expansion of antiretroviral treatment in Thailand 2000-2007: program scale-up and patient outcomes.

Sanchai Chasombat; Michelle S. McConnell; Umaporn Siangphoe; Porntip Yuktanont; Thidaporn Jirawattanapisal; Kimberley K. Fox; Sombat Thanprasertsuk; Philip A. Mock; Peeramon Ningsanond; Cheewanan Lertpiriyasuwat; Somchai Pinyopornpanich

Objective:Thailand began a national antiretroviral (ARV) treatment program in 2000, and all government and some private and university hospitals now provide treatment to eligible HIV-infected patients. We describe program scale-up and patient outcomes from 2000 to 2007. Methods:Data from 839 hospitals in all 76 provinces of Thailand were included in this analysis. Outcomes were assessed for patients initiating ARV treatment from January 2000 to December 2005. Follow-up data through March 2007 were included; lost to follow-up was defined as >3 months late for a follow-up visit. A Cox proportional hazard model was used to assess risk factors for death; the Kaplan-Meier method was used to estimate survival probabilities. Results:Outcome data are reported for 58,008 patients. Among these, 52.2% were male; at treatment initiation, the median age was 34 years, the median CD4 count was 41 cells per cubic millimeter, and 50.5% had AIDS. The initial regimen was nevirapine and 2 nonnucleoside reverse transcriptase inhibitors for 92.4% of patients; median follow-up time was 1.6 years (interquartile range = 0.8-2.4 years). Lost to follow-up occurred in 8.8% of patients. Overall 1-year survival was 0.89 (95% confidence interval = 0.88 to 0.89). Death was significantly associated with male sex, age >40 years, baseline CD4 count <100 cells per cubic millimeter, symptomatic HIV or AIDS, receipt of services at a district or community hospital, and treatment initiation before 2005. Conclusions:National ARV treatment programs can be scaled up rapidly with good patient outcomes. Treatment outcomes among patients in Thailand are comparable to those reported in smaller cohorts in other countries, and survival rates have improved since 2004.


Journal of Clinical Microbiology | 2005

Molecular subtyping of Treponema pallidum from North and South Carolina.

Victoria Pope; Kimberley K. Fox; Hsi Liu; Anthony A. Marfin; Peter A. Leone; Arlene C. Seña; Johanna Chapin; Martha B. Fears; Lauri E. Markowitz

ABSTRACT Patients from five clinics in North and South Carolina who had lesions suggestive of primary or secondary syphilis were evaluated using molecular techniques that allow the differentiation of Treponema pallidum strains on the basis of two variable genes, tpr and arp. Lesion samples were screened for the presence of T. pallidum DNA using PCR for polA, which represents a segment of the polymerase I gene that is unique to the spirochete. Twenty-seven of 154 lesion samples were found to contain T. pallidum, 23 of which had typeable DNA. Seven molecular subtypes were found (10f, 12f, 13f, 14f, 14g, 15f, and 16f); one to four subtypes were identified at each clinic. Subtype 14f was found in 52% of the typeable specimens and was distributed in four of the five clinics. Subtype 16f was found in 22% of specimens and was concentrated at one clinic. Further data are needed to define the role of this technique in examining the epidemiology of syphilis.


Journal of Acquired Immune Deficiency Syndromes | 2010

National program scale-up and patient outcomes in a pediatric antiretroviral treatment program, Thailand, 2000-2007.

Michelle S. McConnell; Sanchai Chasombat; Umaporn Siangphoe; Porntip Yuktanont; Rangsima Lolekha; Naparat Pattarapayoon; Surapol Kohreanudom; Philip A. Mock; Kimberley K. Fox; Sombat Thanprasertsuk

Background:There are limited reports of public sector scale-up of antiretroviral treatment (ART) for HIV-infected children. We describe patient outcomes for HIV-infected children initiating ART in Thailand from 2000 to 2005. Methods:ART-naive patients <15 years old initiating ART from January 2000 to December 2005 were included; follow-up was through March 2007. Survival probabilities were estimated with Kaplan-Meier and hazard ratios for death and loss to follow-up (LTFU) with Cox proportional hazards models. Results:Analysis included 3409 children. Median follow-up time was 1.7 years (interquartile range = 1.0-2.5). Median age at ART initiation was 7.3 years, weight-for-age z score was −2.0, CD4% was 5.0%. ART was initiated in 1428 (41.9%) children at regional/university hospitals and in 689 (20.2%) at district/community hospitals. At last visit, 346 (10.1%) were LTFU and 305 (9.0%) had died. Age <1 (P = 0.008), weight-for-age z score <−2.0 (P < 0.001), CD4% <5% (P < 0.001), and clinical stage C (P < 0.001) were associated with death; district/community hospital patients had a lower hazard of death (P = 0.011). Clinical stage C (P = 0.052) and regional/university hospital (P < 0.001) were associated with increased LTFU. Conclusions:Pediatric ART has been successfully scaled-up in Thailand, including to district/community hospitals. Late entry to care is associated with poorer outcomes, and earlier ART initiation should be prioritized.


International Journal of Std & Aids | 2013

Unexpectedly high HIV prevalence among female sex workers in Bangkok, Thailand in a respondent-driven sampling survey.

C Manopaiboon; Dimitri Prybylski; W Subhachaturas; S Tanpradech; O Suksripanich; U Siangphoe; Lisa G. Johnston; P Akarasewi; Abhijeet Anand; Kimberley K. Fox; Sara Whitehead

The pattern of sex work in Thailand has shifted substantially over the last two decades from direct commercial establishments to indirect venues and non-venue-based settings. This respondent-driven sampling survey was conducted in Bangkok in 2007 among female sex workers (FSW) in non-venue-based settings to pilot a new approach to surveillance among this hidden population. Fifteen initial participants recruited 707 consenting participants who completed a behavioural questionnaire, and provided oral fluid for HIV testing, and urine for sexually transmitted infection (STI) testing. Overall HIV prevalence was 20.2% (95% confidence interval [CI] 16.3–24.7). Three-quarters of women were street-based (75.8%, 95% CI 69.9–81.1) who had an especially high HIV prevalence (22.7%, 95% CI 18.2–28.4); about 10 times higher than that found in routine sentinel surveillance among venue-based FSW (2.5%). STI prevalence (Chlamydia trachomatis and Neisseria gonorrhoeae) was 8.7% (95% CI 6.4–10.8) and 1.0% (95% CI 0.2–1.9), respectively. Lower price per sex act and a current STI infection were independently associated with HIV infection (P < 0.05). High HIV prevalence found among FSW participating in the survey, particularly non-venue-based FSW, identifies need for further prevention efforts. In addition, it identifies a higher-risk segment of FSW not reached through routine sentinel surveillance but accessible through this survey method.


Sexually Transmitted Diseases | 2000

Clinical utility of measuring white blood cells on vaginal wet mount and endocervical gram stain for the prediction of chlamydial and gonococcal infections.

Susan G. Moore; William C. Miller; Irving Hoffman; Kimberley K. Fox; Judy Owen-O'dowd; J. Todd McPherson; April Privette; John L. Schmitz; Peter A. Leone

BACKGROUND White blood cells on endocervical Gram stain and vaginal wet mount are frequently used to predict chlamydial and gonococcal infections. Previous studies provide conflicting evidence for the clinical utility of these tests. GOAL To evaluate the clinical utility of measuring white blood cells on vaginal wet mount and endocervical Gram stain for the prediction of chlamydial infection and gonorrhea. STUDY DESIGN Women undergoing pelvic examinations at 10 county health department family planning and sexually transmitted disease clinics were tested for chlamydial infection by ligase chain reaction assay (n = 4550) and for gonorrhea by culture (n = 4402). Vaginal wet mount and endocervical Gram stains were performed in county laboratories at the time of examination. RESULTS The prevalences of chlamydial infection and gonorrhea were 8.8% and 3.2%, respectively. For detection of chlamydial or gonococcal infection, the likelihood ratio was 2.85 (95% CI, 2.10-3.87) for > 30 white blood cells on vaginal wet mount and 2.91 (95% CI, 2.07-4.09) for > 30 white blood cells on endocervical Gram stain. Similar results were seen for individual diagnoses either of chlamydial infection or of gonorrhea. CONCLUSION Vaginal wet mount and endocervical Gram stain white blood cells are useful for the presumptive diagnosis of chlamydial infection or gonorrhea only in settings with a relatively high prevalence of infection or when other predictors can increase the likelihood of infection.


Morbidity and Mortality Weekly Report | 2017

Japanese Encephalitis Surveillance and Immunization — Asia and Western Pacific Regions, 2016

James D. Heffelfinger; Xi Li; Nyambat Batmunkh; Varja Grabovac; Sergey Diorditsa; Jayantha B. L. Liyanage; Sirima Pattamadilok; Sunil Bahl; Kirsten S. Vannice; Terri B. Hyde; Susan Y. Chu; Kimberley K. Fox; Susan L. Hills; Anthony A. Marfin

Japanese encephalitis (JE) virus is the most important vaccine-preventable cause of encephalitis in the Asia-Pacific region. The World Health Organization (WHO) recommends integration of JE vaccination into national immunization schedules in all areas where the disease is a public health priority (1). This report updates a previous summary of JE surveillance and immunization programs in Asia and the Western Pacific in 2012 (2). Since 2012, funding for JE immunization has become available through the GAVI Alliance, three JE vaccines have been WHO-prequalified,* and an updated WHO JE vaccine position paper providing guidance on JE vaccines and vaccination strategies has been published (1). Data for this report were obtained from a survey of JE surveillance and immunization practices administered to health officials in countries with JE virus transmission risk, the 2015 WHO/United Nations Childrens Fund Joint Reporting Form on Immunization, notes and reports from JE meetings held during 2014-2016, published literature, and websites. In 2016, 22 (92%) of 24 countries with JE virus transmission risk conducted JE surveillance, an increase from 18 (75%) countries in 2012, and 12 (50%) countries had a JE immunization program, compared with 11 (46%) countries in 2012. Strengthened JE surveillance, continued commitment, and adequate resources for JE vaccination should help maintain progress toward prevention and control of JE.


International Journal for Quality in Health Care | 2012

HIVQUAL-T: monitoring and improving HIV clinical care in Thailand, 2002-08.

Sombat Thanprasertsuk; Somsak Supawitkul; Rangsima Lolekha; Peeramon Ningsanond; Bruce D. Agins; Michelle S. McConnell; Kimberley K. Fox; Saowanee Srisongsom; Suchin Chunwimaleung; Robert Gass; Nicole Simmons; Achara Chaovavanich; Supunnee Jirajariyavej; Tasana Leusaree; Somsak Akksilp; Philip A. Mock; Sanchai Chasombat; Cheewanan Lertpiriyasuwat; Jordan W. Tappero; William C. Levine

OBJECTIVE We report experience of HIVQUAL-T implementation in Thailand. DESIGN Program evaluation. SETTING Twelve government hospital clinics. PARTICIPANTS People living with HIV/AIDS (PLHAs) aged ≥15 years with two or more visits to the hospitals during 2002-08. INTERVENTION HIVQUAL-T is a process for HIV care performance measurement (PM) and quality improvement (QI). The program includes PM using a sample of eligible cases and establishment of a locally led QI infrastructure and process. PM indicators are based on Thai national HIV care guidelines. QI projects address needs identified through PM; regional workshops facilitate peer learning. Annual benchmarking with repeat measurement is used to monitor progress. MAIN OUTCOME MEASURE Percentages of eligible cases receiving various HIV services. RESULTS Across 12 participating hospitals, HIV care caseloads were 4855 in 2002 and 13 887 in 2008. On average, 10-15% of cases were included in the PM sample. Percentages of eligible cases receiving CD4 testing in 2002 and 2008, respectively, were 24 and 99% (P< 0.001); for ARV treatment, 100 and 90% (P= 0.74); for Pneumocystis jiroveci pneumonia prophylaxis, 94 and 93% (P= 0.95); for Papanicolau smear, 0 and 67% (P< 0.001); for syphilis screening, 0 and 94% (P< 0.001); and for tuberculosis screening, 24 and 99% (P< 0.01). PM results contributed to local QI projects and national policy changes. CONCLUSIONS Hospitals participating in HIVQUAL-T significantly increased their performance in several fundamental areas of HIV care linked to health outcomes for PLHA. This model of PM-QI has improved clinical care and implementation of HIV guidelines in hospital-based clinics in Thailand.

Collaboration


Dive into the Kimberley K. Fox's collaboration.

Top Co-Authors

Avatar

Michelle S. McConnell

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Rangsima Lolekha

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

William C. Levine

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Joan S. Knapp

United States Public Health Service

View shared research outputs
Top Co-Authors

Avatar

Batmunkh Nyambat

International Vaccine Institute

View shared research outputs
Top Co-Authors

Avatar

Arlene C. Seña

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

James D. Heffelfinger

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jordan W. Tappero

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Myron S. Cohen

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Peter A. Leone

University of North Carolina at Chapel Hill

View shared research outputs
Researchain Logo
Decentralizing Knowledge